Clinical Trials
At Celldex, we are committed to developing safe and effective therapies for patients with devastating diseases for which available treatments are inadequate.
We understand the importance of bringing these therapies to the broadest group of patients as quickly as possible. By taking part in clinical trials, patients can make an important contribution to ongoing research and better understanding of a disease.
Clinical studies collect the information necessary to understand the safety and efficacy of the potential therapy allowing for regulatory review and potential approval.
To learn more about our ongoing clinical trials or to find out if a study is enrolling patients in your area, please visit www.clinicaltrials.gov or email clinicaltrials@nullcelldex.com.
Visit here to learn more about our Compassionate Use or Expanded Access Program.
Candidate | Phase | Identifier | Indication |
---|---|---|---|
Barzolvolimab | Phase 2 | External link opents in a new window NCT05368285 | Chronic Spontaneous Urticaria |
Barzolvolimab | Phase 2 | External link opents in a new window NCT05405660 | Chronic Inducible Urticaria (Cold Contact Urticaria, Symptomatic Dermographism) |